Results 51 to 60 of about 655,557 (182)

Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor [PDF]

, 2014
[[abstract]]Btk and Etk/BMX are Tec-family non-receptor tyrosine kinases. Btk has previously been reported to be expressed primarily in B cells and has an important role in immune responses and B-cell malignancies.
Guo, W;Liu, R;Bhardwaj, G;Yang, JC;Changou, C;Ma, AH;Mazloom, A;Chintapalli, S;Xiao, K;Xiao, W;Kumaresan, P;Sanchez, E;Yeh, CT;Evans, CP;Patterson, R;Lam, KS;Kung, HJ
core   +2 more sources

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Multi‐omics–driven precision medicine

iMeta, EarlyView.
Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li, Zhe Zhao, Yifan Zhang, Yao Ma, Gaofei Hu, Min Zeng, Zhanqun Yang, Zixuan Zhao, Xin Zhou, Wei Hu, Yuxuan Sun, Meng Su, Jun Li, Matthew Whiteman, Wei Fu, Chao Zhong, Lemin Zheng, Long Chen, Hairong Lv, Rongsheng Zhao, Yi Zhun Zhu   +20 more
wiley   +1 more source

BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL

Therapeutic Advances in Hematology, 2020
Older patients account for the majority of patients with chronic lymphocytic leukemia (CLL), and so strategies for managing CLL in this population is of upmost importance.
Andrew Rogers, Jennifer A. Woyach
doaj   +1 more source

Structural Complementarity of Bruton’s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases

Pharmaceuticals, 2023
Bruton’s tyrosine kinase (BTK) is a critical component in B-cell receptor (BCR) signaling and is also expressed in haematogenic and innate immune cells. Inhibition of BTK hyperactivity is implicated in B-cell malignancies and autoimmune diseases.
Asim Najmi, Neelaveni Thangavel, Anugeetha Thacheril Mohanan, Marwa Qadri, Mohammed Albratty, Safeena Eranhiyil Ashraf, Safaa Fathy Saleh, Maryam Nayeem, Syam Mohan   +8 more
doaj   +1 more source

Monocyte inflammation and adaptive immune dysfunction in severe Klebsiella pneumoniae pneumonia

iMeta, EarlyView.
Severe Klebsiella pneumoniae pneumonia combines intense inflammation with failure to control infection, yet the cellular basis is unclear. Using a severity‐focused single‐cell atlas of 708,894 peripheral blood mononuclear cells from 100 individuals, complemented by plasma protein measurements and flow cytometry, we show that disease severity redirects ...
Hongquan Chen, Xiaoling Wang, Xiang Liu, Kui Dong, Yanying Feng, Min Yuan, Shiyi Wang, Fangfang Fan, Yong Tian, Zhiming Kang, Xiushuai Du, Chaolu Hasi, Hong Lu, Wei Guan, Xu Chen, Mengyu Cheng, Wei Wei, Nan Guo, Zhiguo Liu, Xiaotong Qiu, Yiwei Shi, Kun Xiao, Yi Wang, Zhenjun Li   +23 more
wiley   +1 more source

Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia

, 2022
Waldenström macroglobulinemia (WM) is a rare form of non-Hodgkin B-cell lymphoma with a variable clinical presentation that can impact a patient’s quality of life by causing anemia, peripheral neuropathy, serum hyperviscosity, extramedullary ...
Javier Muñoz, Castillo, Jorge J., Jonas Paludo, Jorge J. Castillo, Muñoz, Javier, Paludo, Jonas, Shayna Sarosiek, Sarosiek, Shayna   +7 more
core   +1 more source

The Btk inhibitor AB-95-LH34 potently inhibits atherosclerotic plaque-induced thrombus formation and platelet procoagulant activity [PDF]

, 2022
Background: New antithrombotic therapies with less effect on bleeding are needed for coronary artery disease. The Btk inhibitor ibrutinib blocks atherosclerotic plaque- mediated thrombus formation.
Thomas, Mark R.; id_orcid, Brown, Helena, Poulter, Natalie; id_orcid, Nicolson, Pip; id_orcid, Smith, Christopher, Harbi, Maan, Garcia Quintanilla, Lourdes, Watson, Steve; id_orcid, Rookes, Kieran   +8 more
core   +1 more source

Richter-like transformation of CLL/SLL after a temporary hold of ibrutinib: A case report

Leukemia Research Reports
Bruton tyrosine kinase (BTK) inhibitors are used to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), providing survival benefits over traditional chemoimmunotherapy.
Tung-Lin Chiang, John Frater, Amanda Cashen   +2 more
doaj   +1 more source

Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation

Molecules, 2023
(1) Background: Heart failure (HF) is the final stage of multiple cardiac diseases, which have now become a severe public health problem worldwide.
Wenqi Li, Shuwen Zhu, Jing Liu, Zhigang Liu, Honggang Zhou, Qianyi Zhang, Yue Yang, Li Chen, Xiaowei Guo, Tiantian Zhang, Lingxin Meng, Dan Chai, Guodong Tang, Xiaohe Li, Cheng Yang   +14 more
doaj   +1 more source